Affluent Medical (AFME) | Financial Analysis & Statements
Affluent Medical S.A. | Small-cap | Healthcare
Affluent Medical S.A. | Small-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
4.1M
Gross Profit
856.0K
20.79%
Operating Income
-14.6M
-355.44%
Net Income
-14.7M
-357.92%
EPS (Diluted)
-€0.38
Balance Sheet Metrics
Total Assets
60.9M
Total Liabilities
30.6M
Shareholders Equity
30.3M
Debt to Equity
1.01
Cash Flow Metrics
Operating Cash Flow
-14.5M
Free Cash Flow
-11.5M
Revenue & Profitability Trend
Affluent Medical Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 4.1M | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | 3.3M | 2.1M | 2.4M | 2.5M | 3.1M |
| Gross Profit | 856.0K | -2.1M | -2.4M | -2.5M | -3.1M |
| Operating Expenses | 5.8M | 4.8M | 4.1M | 4.3M | 3.3M |
| Operating Income | -14.6M | -15.4M | -14.3M | -13.3M | -12.6M |
| Pre-tax Income | -14.9M | -15.8M | -15.4M | -15.3M | -14.5M |
| Income Tax | -142.0K | -150.0K | -173.0K | -437.0K | -209.0K |
| Net Income | -14.7M | -15.7M | -15.2M | -14.8M | -14.3M |
| EPS (Diluted) | -€0.38 | -€0.51 | -€0.81 | -€0.88 | -€1.18 |
Income Statement Trend
Affluent Medical Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 12.2M | 5.8M | 7.2M | 14.7M | 7.9M |
| Non-Current Assets | 48.7M | 50.9M | 52.8M | 55.4M | 56.9M |
| Total Assets | 60.9M | 56.7M | 60.0M | 70.0M | 64.8M |
| Liabilities | |||||
| Current Liabilities | 9.5M | 8.4M | 8.6M | 7.3M | 9.8M |
| Non-Current Liabilities | 21.1M | 16.7M | 17.6M | 19.2M | 19.8M |
| Total Liabilities | 30.6M | 25.2M | 26.2M | 26.5M | 29.5M |
| Equity | |||||
| Total Shareholders Equity | 30.3M | 31.5M | 33.8M | 43.5M | 35.3M |
Balance Sheet Composition
Affluent Medical Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -14.7M | -15.7M | -15.2M | -14.8M | -14.3M |
| Operating Cash Flow | -14.5M | -14.0M | -15.4M | -13.3M | -9.9M |
| Investing Activities | |||||
| Capital Expenditures | -147.0K | -171.0K | -146.0K | -334.0K | -304.0K |
| Investing Cash Flow | -480.0K | -171.0K | -146.0K | -160.0K | -304.0K |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 11.7M | 11.7M | 2.9M | 19.1M | 13.7M |
| Free Cash Flow | -11.5M | -12.2M | -11.2M | -12.7M | -9.2M |
Cash Flow Trend
Affluent Medical Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-3.55
Forward P/E
-1.26
Price to Book
1.73
Price to Sales
9.96
PEG Ratio
0.14
Profitability Ratios
Profit Margin
-275.50%
Operating Margin
-124.14%
Return on Equity
-48.69%
Return on Assets
-24.22%
Financial Health
Current Ratio
1.28
Debt to Equity
0.54
Beta
0.66
Per Share Data
EPS (TTM)
-€0.41
Book Value per Share
€0.79
Revenue per Share
€0.11
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| afme | 53.3M | -3.55 | 1.73 | -48.69% | -275.50% | 0.54 |
| Eurobio Scientific | 253.4M | 64.74 | 1.42 | 2.26% | 2.58% | 5.46 |
| Carmat S.A | 24.8M | - | - | 100.52% | -336.56% | -1.13 |
| Median Technologies | 25.6M | -1.02 | - | 74.31% | -109.93% | -0.98 |
| Novacyt S.A | 34.9M | -0.82 | 0.72 | -57.28% | -212.73% | 24.81 |
| Diagnostic Medical | 24.2M | -8.64 | 1.96 | -20.20% | -5.90% | 141.76 |
Financial data is updated regularly. All figures are in the company's reporting currency.